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Abstract
Background: Multiple myeloma osteolytic disease affecting the spine results in vertebral compression fractures.
These are painful, result in kyphosis, and impact respiratory function and quality of life. We explore the impact of
time to presentation on the efficacy of spinal treatment modalities.
Methods: We retrospectively reviewed 183 patients with spinal myeloma presenting to our service over a 2 year period.
Results: Median time from multiple myeloma diagnosis to presentation at our centre was 195 days. Eighty-four patients
(45.9 %) were treated with balloon kyphoplasty and the remainder with a thoracolumbar-sacral orthosis as per
our published protocol. Patients presenting earlier than 195 days from diagnosis had significant improvements
in patient reported outcome measures: EuroQol 5-Dimensions (p < 0.001), Oswestry Disability Index (p < 0.001),
and Visual Analogue Pain Score (p < 0.001) at follow-up, regardless of treatment. Patients presenting after
195 days, however, only experienced benefit following balloon kyphoplasty, with no significant benefit from
non-operative management.
Conclusion: Vertebral augmentation and thoracolumbar bracing improve patient reported outcome scores in
patients with spinal myeloma. However, delay in treatment negatively impacts clinical outcome, particularly if
managed non-operatively. It is important to screen and treat patients with MM and back pain early to prevent
deformity and improve quality of life.
Keywords: Multiple myeloma, Vertebral fracture, Outcome scores, Vertebral augmentation, Thoracolumbar
bracing
Background
In multiple myeloma (MM), osteolytic disease in the
spine is common as the high hematopoietic marrow
content of the vertebrae offers an attractive site for lo-
calisation and growth of neoplastic plasma cells [1, 2].
Through a variety of signal transduction pathways
osteoclasts are preferentially activated and the homeo-
static balance of bone remodelling shifts towards re-
sorption [2, 3]. Localised osteoporosis ensues and may
result in vertebral body compression fractures (VCFs)
[3, 4]. This is potentially exacerbated by high dose ster-
oid treatment used in the treatment of MM, further
weakening the bone.
Multiple VCFs and increasing thoracic kyphosis have
been shown to adversely affect functional status in the
osteoporotic population and are associated with signifi-
cantly reduced lung function and increased pulmonary
complications [5–9]. In the non-osteoporotic adult
population, a kyphotic deformity of the spine has also
been shown to adversely affect health related quality of
life scores [10].
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Augmentation of a fractured vertebral body with acrylic
cement has been shown to restore its strength and prevent
further kyphosis [11–13]. This augmentation can be per-
formed using minimally invasive techniques such as percu-
taneous vertebroplasty or balloon kyphoplasty (BKP). Both
techniques have been shown to significantly reduce pain
from VCFs and improve function in patients with meta-
static disease and myeloma [14–17]. Functional outcome is
particularly important in patients with MM as the life ex-
pectancy of this patient cohort continues to increase with
the introduction of modern chemotherapeutic treatment
regimens [2].
We describe the clinical and radiographic parameters
of patients with an established diagnosis of MM present-
ing to our tertiary referral spinal service, and their re-
sponse to treatment for their VCFs. We assess response
by the change in patient reported outcome scores fol-
lowing intervention. Our objectives are: to explore the
way in which spinal deformity affects clinical outcomes,
and to explore the impact of time to presentation on the
efficacy of spinal treatment modalities.
Methods
Patients
This study was performed at a national tertiary centre
for the treatment of spinal MM, using a protocol ap-
proved by our Institutional Review Board (Research
Governance Team, Research & Innovation, Royal Na-
tional Orthopaedic Hospital, Stanmore, UK; Reference:
SE14.019). We routinely collect demographic and clin-
ical outcome data on all patients and patients consent to
their data being used for the purposes of research and
analysis. Data collected on patients presenting with MM
bone disease involving the spinal column between June
2013 and May 2015 was retrospectively analysed. We in-
cluded all adult patients in whom MM was the primary
cause for their VCFs.
Clinical data collected included patient demographics,
date of MM diagnosis, number and level of VCFs, treat-
ment given, and time from diagnosis of MM to presenta-
tion at our service. We analysed clinical and radiographic
outcome variables at time of presentation and at follow-
up 6-weeks after treatment. Clinical outcome measures
were assessed using patient reported health related quality
of life scores as discussed below. Patients were treated ei-
ther with both BKP and a front-opening thoraco-lumbar-
sacral orthosis (TLSO), or with a TLSO alone in line with
our published guidelines for management of spinal mye-
loma (described below) [18].
We excluded patients with missing clinical outcome
scores, inadequate radiographs (radiographs not taken
according to protocol described below), VCFs due to a
diagnosis other than MM, cord compression, or with
neurological deficit. We also excluded patients if they
had had previous spinal fusion surgery or cement aug-
mentation (vertebroplasty or BKP) prior to presentation
at our institution, or if they were lost to follow-up.
Radiology
All patients were referred with whole spine magnetic
resonance (MR) scans. All patients had standardised,
full length, standing, lateral spinal radiographs taken at
presentation (and 6 weeks post-BKP). Our imaging soft-
ware took into account and adjusted for magnification
when taking measurements on radiographs (calibrated
for 5 % magnification). All measurements were done
digitally using Patient Archiving and Communication
Software (PACS, Sectra, Sweden). Radiographic out-
come measures collected included: thoracic kyphosis,
lumbar lordosis and sagittal vertical axis. Thoracic ky-
phosis was measured as the angle between the inferior
vertebral body end plate of T12 and the superior end
plate of T4. Similarly, lumbar lordosis was measured
from the superior endplate of S1 to the superior end
plate of L1. Sagittal vertical axis was measured as the
horizontal distance from the posterior-superior verte-
bral body end plate of S1 to a vertical plumb line drawn
from the C7 vertebra. Additionally, we recorded ky-
phosis between T5 to T10 – mid-thoracic kyphosis,
and T10 to L2 – thoracolumbar kyphosis. Normal
ranges are published and listed in Table 1 [19–22]. Fur-
ther information on the clinical importance of these
measurements and an example case are illustrated in
our supplementary data (Additional file 1).
For patients undergoing BKP, vertical height of the ver-
tebral body was measured before and after the procedure
and compared to the height of adjacent normal vertebral
bodies to obtain the percentage of height lost after VCF,
and the percentage of height restored after BKP. These
measurements were taken at the anterior border and the
mid-point of the vertebral bodies (illustrated in our
supplementary data in Additional file 1).
Table 1 Results of the radiological parameters recorded at
presentation. A negative sagittal vertical axis (SVA) indicates that
the centre of gravity of the spine falls behind the superior endplate
of S1. The mean thoracic kyphosis (TK) is higher and the mean
lumbar lordosis (LL) is lower (more kyphotic) than in the literature
reflecting our patient population. It can also be seen that
this is mostly due to kyphosis in the mid thoracic (MTK) and
thoracolumbar (TLK) regions [19–22]
TK (°) LL (°) SVA (mm) MTK (°) TLK (°)
Mean 56.2 48.4 53.5 38.4 21.3
Std. deviation 18.2 16.5 52.1 16.8 16.2
Minimum 9 3 −52 5 −10
Maximum 106 94 198 85 67
Population mean 40 ± 10 56 ± 13 7 ± 32 15 ± 4 1 ± 9
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Interventions
Patients were treated with either TLSO alone, or with
BKP and a TLSO. MR scans and clinical examination
were used to determine the state of healing of the spinal
fractures at time of presentation. Fractures which had
completely healed did not require either form of treat-
ment. For those patients with unhealed fractures, the
spinal instability neoplastic score (SINS) was used to de-
termine their stability. The SINS score was calculated
from the MR scans. For those patients with fractures
classed as ‘stable’ (score of 0–6) or ‘impending instabil-
ity’ (score of 7–12) using the SINS score, a TLSO was
prescribed in order to support the vertebral column and
prevent further deformity whilst healing occurred. For
those patients with fractures classed as ‘unstable’ (score
of 13–18) a BKP was performed to prevent further de-
formity from occurring. Regardless of stability, patients
with fractures which were painful were offered BKP,
where medically fit for surgery. This was assessed using
the visual analogue score, and a score of 6/10 or more
was our cut-off. All patients undergoing BKP were also
treated with a TLSO post-operatively.
Where a TLSO was used, this was a front-opening
orthosis which was worn when the patient was standing
or mobilising, but which could be taken off in bed. The
brace was worn for a period of 3 months whilst fracture
healing occurred. BKP was performed under general an-
aesthesia, with the patient prone, under fluoroscopic
guidance and with antibiotic prophylaxis. Unilateral,
para-spinal stab incisions were made and a trochar was
introduced into the vertebral body through the pedicle.
The balloon was then inflated to create a cavity in the
vertebral body and the space then filled with cement.
Post-operatively patients were allowed to mobilise in
their TLSO and were discharged the following day.
Outcome measures
Clinical outcomes measures utilised to assess health
related quality of life included the validated scoring mea-
sures of Euro-Qol 5 Dimensions (EQ-5D), Oswestry
Disability Index (ODI), and the Visual Analogue Score
for the trunk (VASB). These scores were recorded at the
time of initial presentation to our service and were re-
peated at follow-up 6 weeks after intervention. The
minimum clinically important difference in scores was
taken as 0.090 points for EQ-5D, 8.8 points for the ODI,
and 1.2 points for the VASB [23–25].
Statistical analysis
Statistical analysis was performed using SPSS 16.0 (IBM,
New York, USA). Data are presented as mean ± standard
deviation, or as medians with a range. Correlation between
radiographic and clinical variables was analysed using
Pearson’s coefficient for parametric data and Spearman’s
rank correlation for non-parametric data. We also divided
patients into groups based on time from diagnosis to
presentation (in groups of 30 days intervals) and assessed
for differences in radiological and clinical parameters.
Comparison between groups was carried out using paired
and independent t-tests for parametric data, and Wilcoxon
signed ranks and Mann-Whitney U tests for non-
parametric. Statistical significance was considered to be a
2-tailed p-value <0.05.
Results
Patients
One hundred and ninety six patients meeting our inclu-
sion criteria were reviewed in our tertiary spinal MM
service between June 2013 and May 2015. Thirteen
patients were excluded due to presence of cord compres-
sion, neurological deficit, or previous surgery, leaving 183
patients with symptomatic MM of the spine for subse-
quent analysis.
The median age was 66 years (range: 37–91 years).
There was a male preponderance (male:female ratio of
1.69:1). Of the patients seen 136 (74.3 %) had a new
diagnosis of myeloma and 47 (25.7 %) presented after a
relapse. Ninety-three patients (50.8 %) had IgG subtype
MM, 22 (12.0 %) had IgA, 29 (15.9 %) had light chain
subtype and 9 (4.9 %) had other subtypes of MM. In 30
patients (16.4 %) the subtype was not known. Sixty five
patients (35.5 %) had autologous stem cell transplant
prior to presentation. Four patients (2.2 %) were taking
oral bisphosphonates at time of presentation and 113
(61.8 %) were being treated with intravenous bispho-
sphonates. There was no active bisphosphonate treat-
ment recorded for 66 patients (36.0 %) at time of
presentation.
The mean number of vertebral fractures secondary to
MM at time of presentation was 3.7 ± 2.7 levels. The me-
dian time to presentation was 195 days (interquartile
range: 72–996 days). The median duration of spinal
follow-up was 206 days (interquartile range: 92–418
days). Twenty-two patients (12.02 %) died, at a median
time of 258 days from presentation at our unit (range:
97–470 days). The data are summarised in Table 2, along
with actual ranges.
Radiological parameters
The mean lumbar lordosis was 48.1° ± 17.2°, mean thor-
acic kyphosis was 55.2° ± 18.9°, mean sagittal vertical axis
was 55.1 mm ± 51.6 mm. The mean mid-thoracic ky-
phosis was 38.1° ± 17.4°, and thoracolumbar kyphosis
was 20.7° ± 15.5°. Table 1 shows the radiological parame-
ters recorded at presentation and the population normal
values [19–22]. The mean SINS score at presentation
was 12.75 ± 2.03 (range: 6–16). There was no correlation
of any radiological parameters with age or sex.
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The sagittal vertical axis was 3.5 ± 25.8 mm in those
presenting earlier than 30 days and significantly worse
(58.2 ± 51.5 mm) in those presenting later than 30 days
from diagnosis of MM (p < 0.001) (Fig. 1). However, only
15 patients (8.1 %) presented earlier than 30 days. Time
from diagnosis to presentation did not correlate with
any other radiological parameters, number or location of
fractures, or SINS score. Standing radiographs were not
available post-treatment to assess for change in radio-
logical parameters.
Management of patients
Eighty four patients (45.9 %) underwent BKP and 94
(51.37 %) were managed non-operatively, with a TLSO,
in line with our local protocol as described above. Five
patients (2.73 %) did not require any form of spinal
treatment and are not included in analysis of follow-up.
Twenty-eight patients (33.3 %) undergoing BKP had a
SINS score indicating ‘impending instability’ (between 9
and 12) and in these patients the indication for BKP was
pain. Thirty-two patients (34.0 %) treated in a TLSO only
has a SINS score indicating an ‘unstable’ spine, but were
medically unfit for surgery. Table 3 gives details, including
radiological parameters of the patients in each group.
For the 84 patients who underwent BKP, a median of
2 levels (range: 0–6 levels) were operated on. There
were no immediate acute adverse reactions. For patients
undergoing BKP, there was a statistically significant
improvement in anterior-vertebral height restoration of
3.0 % ± 5.5 % (range: 0–38.1 %) (p < 0.001) and mid-
vertebral height restoration of 3.4 % ± 6.0 % (range: 0–
31.8 %) (p < 0.001) which was not affected by time to
presentation or time from presentation to BKP. No pa-
tient lost further vertebral height post BKP. Vertebral
height restoration data was available in all patients
undergoing BKP.
Patient-reported outcomes
At presentation, the mean EQ-5D was 0.435 ± 0.201, the
mean ODI was 49.1 ± 16.7, and the mean VASB was 6.1
± 2.5 for all patients. A greater number of mid-thoracic
(T3-T10) fractures was found to correlate with a poorer
EQ-5D score (p = 0.04). Increasing sagittal vertical axis
correlated negatively with ODI (p = 0.027). Loss of lum-
bar lordosis (p = 0.016) and increased thoracolumbar ky-
phosis (p = 0.036) were correlated with a poorer EQ-5D
score at follow-up, regardless of treatment. Increasing
thoracolumbar kyphosis was also associated with in-
creased VASB at follow-up in the BKP group (p = 0.04).
The mean VASB at presentation was higher in patients
undergoing BKP (6.3 ± 2.3) compared to those treated
non-operatively (5.5 ± 2.9, p = 0.031). For all patients, at
follow-up 6 weeks after treatment with a TLSO, or
6 weeks after BKP, there was a significant improvement
in outcome scores. The mean post-treatment EQ-5D for
all patients was 0.548 ± 0.219 (improvement of 0.107
points, p < 0.001), the mean ODI was 42.3 ± 18.3 (im-
provement of 6.8 points, p = 0.003), and the mean VASB
was 3.2 ± 2.7 (improvement of 2.7 points, p < 0.001).
These results are summarised in Fig. 2.
In the BKP group there was a post-operative improve-
ment in EQ-5D (p < 0.001, 0.144 points), ODI (p < 0.001,
7.2 points) and VASB (p < 0.001, 3.6 points) when com-
pared to pre-operative scores. For those patients treated
without BKP, there was an improvement in ODI of
7.7 points (p = 0.005) and in the VASB of 1.7 points
(p < 0.001) compared to pre-treatment scores. These
results are summarised in Table 3 and Fig. 3.
Table 2 Basic characteristics of patients sampled. Data presented
as number of patients in each group or as a median accompanied
by full range (interquartile ranges listed in Results section)
Patient characteristic (N = 183) N (%) or median
(range)
Age 66 years (37–91 years)
Gender:
Male 115 (62.8 %)
Female 68 (37.2 %)
Disease status:
Newly diagnosed 136 (74.3 %)
Relapsed 47 (25.7 %)
Chain Isotype:
IgG 93 (50.8 %)
IgA 22 (12.0 %)
Light chain 29 (15.9 %)
Other 9 (4.9 %)
Missing 30 (16.4 %)
Time from diagnosis to presentation
All patients 195 days (11–5090 days)
New diagnosis of MM 109 days (11–1902 days)
Relapse of MM 1929 days (171–5090 days)
Previous autologous stem cell transplant 65 (35.5 %)
Bisphosphonate therapy
Intravenous 113 (61.8 %)
Oral 4 (2.2 %)
None recorded 66 (36.0 %)
Acute vertebral compression fractures:
Number of fractures per patient 3 fractures (0–15 fractures)
Thoracic region (number of patients) 149 (81.4 %)
Lumbar region (number of patients) 111 (60.7 %)
Thoracic and lumbar fractures (number
of patients)
85 (46.5 %)
No non-healed fractures 7 (3.8 %)
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Effect of disease stage and time to presentation
There was no significant difference in patient reported
scores at presentation between newly diagnosed patients
and those with relapsed disease. There was also no correl-
ation between pre-existing radiological parameters and
clinical benefit from either treatment group. Increasing
time to presentation did not correlate with scores at pres-
entation but on subgroup analysis it was found that pa-
tients presenting and treated within 195 days (our median
time to presentation) from diagnosis had a significant
improvement in clinical scores regardless of treatment.
For all patients undergoing BKP and presenting earlier
than 195 days (37 patients, 44.1 %) the mean improve-
ment in EQ-5D score was 0.171 points (p < 0.001), mean
improvement in ODI score was 10.4 points (p < 0.001),
and mean improvement in VASB score was 4.3 points
(p < 0.001). In those patients presenting after 195 days
(47 patients, 55.9 %) there was a reduced improvement
in EQ-5D (0.122 points improved, p < 0.05), and VASB (3.1
points, p < 0.001), although still a statistically significant
improvement compared to pre-treatment. However, the
improvement in ODI was no longer significant (4.2 points
improved, p = 0.09) compared to pre-treatment scores.
In those patients treated with TLSO alone, and present-
ing earlier than 195 days (48 patients, 51.1 %), the mean
improvement in EQ-5D score was 0.118 points (p = 0.009),
mean improvement in ODI score was 11.7 points (p =
0.007), and mean improvement in VASB score was 2.8
points (p < 0.001). However in those patients presenting
after 195 days (46 patients, 48.9 %) there was no significant
improvement in EQ-5D (0.016 points worse, p = 0.78),
ODI (2.5 points improved, p = 0.399) or VASB (0.35 points
improved, p = 0.422). These findings are summarised in
Fig. 3 and a breakdown of clinical response by treatment
group is illustrated.
Discussion
The optimal management of spinal disease in myeloma
patients continues to be a controversial area. The in-
creasing life expectancy of these patients with the use of
more effective chemotherapy regimens makes it all the
more important to avoid spinal deformity early on in
their management. The mechanisms by which sequential
vertebral fractures and progressive spinal deformity and
sagittal mal-alignment occur are examined in more de-
tail in our supplementary data (Additional file 1).
The effects of spinal deformity
We have assessed spinal deformity using measures of
global alignment and have demonstrated that patients
presenting later than 30 days from diagnosis have signifi-
cantly greater deformity (as assessed by sagittal vertical
axis) than those presenting earlier. Although only a
small proportion of our patients presented earlier than
30 days, it is important to be aware that sagittal decom-
pensation occurs early, and may be sudden (as illustrated
in our supplementary data in Additional file 1).
The EQ-5D is a patient reported clinical outcome
measure assessing pain, mobility, psychological state and
ability to carry out activities of daily living. A higher
Fig. 1 Mean Sagittal Vertical Axis by Time to Presentation. Chart demonstrating the mean sagittal vertical axis (SVA) for patients presenting between
time periods as illustrated. The error bars shown illustrated the standard error. Patients presenting earlier than 30 days from diagnosis of MM had a
significantly lower SVA (within the normal population range) than those presenting later
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score represents better function. The ODI is a clinical
outcome measure where patients grade severity of symp-
toms and their effect on daily activities. This is assessed
over 10 domains and is a well-established and validated
outcome measure [26]. These clinical outcomes scores
were adversely affected by deformity (sagittal vertical
axis) and number of fractures at presentation. Deformity
in the lumbar (lordosis) and thoracolumbar (kyphosis)
regions also negatively impacted outcomes scores at
post-treatment follow-up. Patients with established dis-
ease in the thoracolumbar region had a poorer response
to treatment with BKP, perhaps due to ongoing mechan-
ical instability from established deformity (illustrated in
our supplementary data in Additional file 1).
We did not see a correlation between times from diag-
nosis to presentation and radiological or clinical parame-
ters, apart from sagittal vertical axis. However, this may
be because we had only 15 patients (8.1 %) presenting
within 30 days of diagnosis. Thus we have an insufficient
sample size to draw accurate conclusions about when
deformity occurs and when clinical status begins to de-
teriorate. However, deformity is associated with adverse
Table 3 Table showing the breakdown of demographics, radiological parameters and outcome scores for patients who underwent
BKP and those treated with TLSO alone. It can be seen that there is no significant difference between demographics between groups,
but that patients who underwent BKP had a significantly higher presentation VASB score than patients treated non-operatively. Post
treatment patients treated with BKP had a better EQ-5D score than those treated with TLSO alone
BKP patients = 84 TLSO patients = 94 Statistical
significance
(* = p < 0.05)
Mean ± StDev/Median (range) Mean ± StDev/Median (range)
Age 65.2 ± 10.7 years 65.6 ± 12.4 years p = 0.845
Gender: p = 0.738
Male 53 (63.1 %) 57 (60.6 %)
Female 31 (36.9 %) 37 (39.4 %)
Disease status: p = 0.670
Newly diagnosed 62 (73.8 %) 72 (76.6 %)
Relapsed 22 (26.2 %) 22 (23.40 %)
Chain Isotype: p = 0.989
IgG 41 (48.8 %) 49 (52.1 %)
IgA 12 (14.3 %) 10 (10.6 %)
Light chain 12 (14.3 %) 17 (18.1 %)
Other 5 (5.9 %) 4 (4.3 %)
Missing 14 (16.7 %) 14 (14.9 %)
Time from diagnosis to presentation 232 days (98–996 days) 141 (55–992 days) p = 0.349
Number of patients who died 6 (7.14 %) 14 (14.9 %) p = 0.103
Radiological parameters
Number of fractures per patient 3 fractures (2–5 fractures) 3 fractures (1–5 fractures) p = 0.282
Thoracic Kyphosis (TK) 56.4° ± 18.5° 53.2° ± 19.4° p = 0.289
Lumbar Lordosis (LL) 47.2° ± 17.4° 48.6° ± 16.8° p = 0.601
Sagittal Vertical Axis (SVA) 58.7 ± 49.0 mm 49.6 ± 55.0 mm p = 0.288
Mid-thoracic Kyphosis (MTK) 36.9° ± 16.7° 38.8° ± 18.0° p = 0.491
Thoracolumbar Kyphosis (TLK) 22.6° ± 16.2° 18.9° ± 14.6° p = 0.140
SINS Score 13.0° ± 1.6° 12.4° ± 2.5° p = 0.076
Patient reported outcome scores
EQ-5D (presentation) 0.442 ± 0.220 0.463 ± 0.230 p = 0.526
ODI (presentation) 51.0 ± 16.6 46.2 ± 19.0 p = 0.085
VASB (presentation) 6.3 ± 2.3 5.5 ± 2.9 p = 0.031*
EQ-5D (6 weeks post treatment) 0.593 ± 0.192 0.480 ± 0.240 p = 0.008*
ODI (6 weeks post treatment) 42.6 ± 16.2 40.8 ± 22.1 p = 0.637
VASB (6 weeks post treatment) 2.8 ± 2.3 3.5 ± 3.1 p = 0.135
P values which are statistically significant have been highlighted with an '*'
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Fig. 2 (See legend on next page.)
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clinical scores at presentation and follow-up, and it is lo-
gical to aim to treat patients before deformity occurs.
Treatment should be aimed at preventing sequential
fractures and progressive deformity and should be com-
menced early. The lumbar and thoracolumbar regions
are of particular importance as deformity in these re-
gions also results in positive sagittal imbalance [27].
Treatment may be in the form of a thermoplastic TLSO
or cement augmentation [18]. In addition, all patients
with MM and spinal involvement should be considered
for bone protection treatment, such as bisphosphonates.
The effects of time to presentation on benefit from
intervention
BKP has been reported to restore height to a fractured
vertebra and improve the kyphotic deformity of the ver-
tebral body by over 50 % if the BKP is performed within
3 months of the onset of pain in the osteoporotic popu-
lation [13]. BKP and percutaneous vertebroplasty have
also been used successfully in the setting of MM to pre-
vent deformity and treat pain [15–17, 28, 29]. We found
that vertebral body height was only restored by a small
amount in our cohort, but importantly, no further height
was lost after BKP was performed. This has also been
demonstrated by previous authors [30, 31]. We cannot
ascertain from our data, whether this led to a halt in
overall deformity progression. Patients undergoing BKP
had significantly improved EQ-5D and VASB scores
regardless of time to treatment. ODI, however, only
improved if patients were treated sooner than 195 days
from diagnosis.
Patients treated non-operatively with a TLSO were
also seen to have a statistically significant clinical im-
provement in EQ-5D, ODI and VASB scores if treated
within 195 days of diagnosis. When presenting later,
however, there was no significant benefit of treatment in
a TLSO.
We offered BKP to patients with painful or unstable
fractures. However, we found no difference in SINS
score between our BKP and TLSO groups. This was
partly because a third of patients treated in a TLSO were
classed as ‘unstable’, but were not medically fit for sur-
gery, and partly because a third of patients underwent
cement augmentation for pain rather than instability.
The latter is reflected in the difference observed between
VASB at presentation in BKP and non-BKP groups.
Our results indicate that regardless of treatment, early
intervention benefits patients. Delay in treatment lessens
this benefit, particularly in patients managed without
BKP. It is unclear from our data whether operative or
non-operative treatment is superior when instituted
early, however, BKP may be more suitable for treatment
of patients with delayed presentations. This may, in
particular, adversely impact those patients with delayed
presentations who are not medically fit for surgery.
Strengths and weaknesses
This was a single centre series with a large cohort of pa-
tients managed according to the same clinical protocols.
Thus we are able to perform multiple correlations. How-
ever, as this was a retrospective analysis of data, it is
difficult to determine the exact duration of symptoms
and the period over which multiple VCFs occurred. It is
also difficult to assess the progression of the spinal de-
formity with sequential VCFs. The time from onset of
back pain to presentation could not be reliably assessed
for several reasons. Patients may have had back pain for
many months prior to diagnosis, or have developed back
pain related to interval fractures or marrow infiltration,
particularly in those with relapsed MM. Time from onset
of back pain to presentation may indeed be an important
parameter which could be addressed in future studies
examining the relationship between time from onset of
back pain to development of deformity and adverse clin-
ical outcome in patients with MM.
Patients were treated with BKP and a TLSO, or a
TLSO alone depending on the degree of pain and stabil-
ity. In general patients with higher VASB scores and less
stable vertebral fractures at presentation were offered
BKP. This makes direct comparisons of outcomes be-
tween these groups of patients problematic as they may
be inherently different. Nevertheless, some patients with
pain/less stable vertebral fractures were treated with a
TLSO only and significant improvement was seen in
post-treatment VASB in both groups.
This was a retrospective study including all newly re-
ferred myeloma patients with adequate data and we did
not apply specific exclusion criteria. Although we exam-
ined the relationship between demographics, time to
presentation and outcome, other factors may account
for differences between groups.
Our follow-up is reported at 6 weeks post-treatment
as we do not have sufficient data from 3 and 6 month
follow-up time points. Patients often did not attend sub-
sequent appointments for varying reasons, and some de-
veloped additional lesions which could confound the
(See figure on previous page.)
Fig. 2 Difference in Patient Reported Scores Before and After Treatment. Results of the patient reported clinical scores recorded at presentation
and follow-up 6 weeks post-intervention with 95 % confidence intervals shown. For EQ-5D a score of 1.000 represents the best possible health
status and 0 represents the worst. For ODI and VASB 0, represents the best possible health state and 100 and 10 represent the worst, respectively.
Annotation with ‘*’ denotes a statistically significant difference (p < 0.05)
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Fig. 3 (See legend on next page.)
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outcomes [15, 29]. It is our experience that patients
cannot reliably distinguish between symptoms from
treated and new fractures. For this reason we do not
routinely record scores after 6 weeks and less than 10 %
of included patients had scores recorded at 3 and
6 months. We have therefore not reported longer term
follow-up data. However, in the absence of further VCFs,
the improvement in pain and outcome scores following
cement augmentation has been shown to persist up to
5 years [16].
Existing literature on spinal myeloma focuses on cement
augmentation of individual VCFs but does not describe
overall spinal deformity (sagittal mal-alignment) nor the
impact of time to presentation on efficacy of treatment.
Existing literature also does not report on the results of
non-operative treatment of spinal myeloma with a TLSO.
Conclusions
Our results demonstrate that patients with spinal involve-
ment of MM develop significant deformity. Health related
quality of life scores are poor in the setting of these de-
formities, particularly when affecting the thoracolumbar
junction. Treatment at a specialist spinal myeloma unit
improves clinical scores but those patients with delayed
presentation, or significant deformity may benefit less
from treatment. This reduced benefit is particularly seen
in patients treated non-operatively. We suggest that all
patients with MM and back pain or an early clinical spinal
deformity be screened for spinal lesions as a matter of
urgency and urgent referral to a specialist spinal myeloma
unit be considered.
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